Human study PLS-00166

Serum thymosin beta4 levels in patients with hepatitis B virus-related liver failure.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

Serum thymosin beta4 levels in patients with hepatitis B virus-related liver failure.primary · World journal of gastroenterology · 2010-02-01 · PMID 20128033 · DOI

Design and participants

Design: Cross-sectional study
Population: Patients with acute-on-chronic liver failure, chronic liver failure, compensated liver cirrhosis or chronic hepatitis B related to HBV infection, plus healthy controls
Conditions: Hepatitis B virus-related liver failure, Acute-on-chronic liver failure, Chronic liver failure, Compensated liver cirrhosis, Chronic hepatitis B
Setting: Hospitalized patients assessed on admission
Planned enrollment (registry): Not reported
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported
Funding: Research Support, Non-U.S. Gov't (publication type); funder not named in the record
Authors’ conflicts: Not stated

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety.

Monitoring: Not applicable; no intervention was given.

The authors concluded (paraphrased): Serum thymosin beta4 may serve as an important potential predictor of liver failure caused by chronic HBV infection.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

inappropriate endpoint: Endogenous serum thymosin beta4 was measured as a biomarker. The compound was never administered, so no treatment effect can be inferred.
abstract only: Only the abstract is available in the record, and its results sentence is truncated before the p-value.
confounding: The abstract describes cross-sectional group comparisons with no adjustment for confounders.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves dry eye signs and symptoms: not eligible (not primary study) for “Ocular discomfort and corneal staining”
Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”

Where each value comes from

author_conclusion: PMID 20128033, abstract (Conclusion, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
design: PMID 20128033, abstract (Methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
limitations: PMID 20128033, abstract (Results, sentence 1 (truncated)) · extracted by AI (automated, not verified by a person) · abstract only
participants: PMID 20128033, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
population: PMID 20128033, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).